May 4-5, 2022 MIT Webconference

The Longwood Healthcare Leaders Spring meeting is centered on MIT’s Koch Institute via webconference with leading biopharma CEOs, heads of R&D, top academic researchers, and healthcare investors, co-hosted by Nobel laureate and Biogen/Alnylam co-founder Phil Sharp.

Featured Speakers

 
 

These meetings are focused on accelerating the translation of discoveries into medicines to help patients; substantial donations enabled by these meetings benefit Life Science Cares, The Boston Foundation, BSO, Harvard Medical School, MIT, and other charities.

LONGWOOD HEALTHCARE LEADERS SPRING WEBCONFERENCE

AGENDA | MAY 4-5, 2022

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

WEDNESDAY, MAY 4, 2022

10:40 am

PLACING PATIENTS AT THE CENTER

Michael Ackermann, Chair, Tarsus

Stewart Campbell, CEO, Axial Therapeutics

Mary Fisher, CEO, Colorescience

Joanne Waldstreicher, CMO, Johnson & Johnson

Moderator: Al Beardsley, COO, Galera Therapeutics

11:15 am

MAINTAINING CROSS-INDUSTRY COLLABORATION

Angus Grant, CBO, BeiGene

Aamir Malik, Chief Business Innovation Officer, Pfizer

Rachel Mears, Partner, Jeito Capital

Amit Mehta, Head, Partnering, gRED, Genentech

Amanda Wagner, CEO, Immunitas

Moderator: Gaurica Chacko, Global Domain Leader, Life Sciences, Wipro

1:00 pm

ADVANCING PLATFORM TECHNOLOGIES

Manuel Aivado, CEO, Aileron Therapeutics

Pablo Cagnoni, CEO, Rubius Therapeutics

Simon Harnest, CIO, Metagenomi

Phil Johnson, CEO, Interius Bio

David Southwell, CEO, TScan Therapeutics

Moderator: Michal Preminger, Head, Innovation, Johnson & Johnson, East North America

1:50 pm

CLINICAL TRIAL EFFICIENCY

Christian Antoni, Chief Development Officer, EQRx

Aoife Brennan, CEO, Synlogic

Marc Lipsitch, Director, Center for Communicable Disease Dynamics, Harvard

James Sapirstein, CEO, First Wave Therapeutics

Moderator: Alise Reicin, CEO, Tectonic Therapeutics

9:20 am

HOW M&A SPURS INNOVATION

Liz Leveille, Head, BD&L Boston & European Innovation Hubs, Merck

Ivana Magovcevic-Liebisch, CEO, Vigil Neuroscience

Greg Mayes, CEO, Antios Therapeutics

Matthias Müllenbeck, Head, Global BD & Alliance Management, Merck KGaA

Moderator: Chad Shear, Principal, Fish & Richardson

8:50 am

SPOTLIGHT ON MIT INNOVATION

Regina Barzilay, Distinguished Professor for AI & Health, School of Engineering, MIT

Kipp Weiskopf, Valhalla Fellow, Whitehead Institute for Biomedical Research

Jonathan Weissman, Professor, Biology, MIT

Moderator: Jane Wilkinson, Executive Director, Koch Institute, MIT

8:30 am

REGULATORY KEYNOTE

Peter Marks, Director, Center for Biologics Evaluation and Research, FDA

Andy Plump, President, R&D, Takeda

Moderator: Christoph Westphal, General Partner, Longwood Fund 

9:50 am

EXPEDITING RESEARCH FOR TREATMENTS AND CURES

Chun-Lin Chen, CEO, Medicilon

Raj Devraj, CEO, Rectify Pharmaceuticals

Bill Hinshaw, CEO, Axcella Therapeutics

Peter Lebowitz, Global Oncology Therapeutic Area Head, Janssen

Reenie McCarthy, CEO, Stealth BioTherapeutics

Moderator: Chen Schor, CEO, Adicet Bio

2:50 pm

DRUG DISCOVERY SCIENCES

Annalisa D’Andrea, President & Chief Scientific Officer, ImmuneID

Marion Dorsch, President & CSO, Atavistik Bio

Larry Hamann, CEO, Interdict Bio

Cigall Kadoch, Associate Professor, Dana-Farber Cancer Institute

Saul Kato, CEO, Herophilus

Moderator: Art Krieg, CSO, Checkmate Pharmaceuticals

3:40 pm 

CULTIVATING AN ECOSYSTEM OF PARTNERS

Percival Barretto-KoCEO, Plexium

Marianne De Backer, EVP, Head, Global BD&L, Bayer

Aakanksha Khandelwal, Global Commercial Lead, Oncology, Daiichi Sankyo

Chris Viehbacher, Founding Partner, Gurnet Point Capital

Henry Walke, Director of the Center for Preparedness and Response, CDC

Moderator: Ari Schaefer, Co-President, Klick Health

4:10 pm

MAKING SMART INVESTMENTS

Lori Hu, Managing Director, Vertex Ventures HC

Matthias Kleinz, SVP, Translational Sciences, UPMC Enterprises

Kyle Lefkoff, General Partner, Boulder Ventures

Judith Li, Partner, Lilly Asia Ventures

Marie-Claire Peakman, Principal, Pfizer Ventures

Moderator: Aleks Radovic-Moreno, Partner, Longwood Fund

2:20 pm

DESIGNING THE DEAL

Robert Blum, CEO, Cytokinetics

Jennifer Cayer, CBO, Pulmocide

Travis Engelman, Head, BD, Cytiva

Philippe Lopes-Fernandes, CBO, Ipsen

Brian Silver, CFO, TScan Therapeutics

Moderator: Brian McVeigh, CEO, Code Biotherapeutics

11:50 pm

CREATING A WORLD WITHOUT DISEASE

Mike Devoy, CMO, Bayer Pharmaceuticals

Bettina Cockroft, CMO, Sangamo

Mike Rosenblatt, Senior Partner, Flagship Pioneering

Ryan Saadi, CEO, Tevogen Bio

Skip Virgin, CSO, Vir Biotechnology

Moderator: Bill Hait, Global Head, External Innovation, Johnson & Johnson

12:25 pm

ACCELERATING DRUG DEVELOPMENT

JC Gutierrez-Ramos, CSO, Danaher

Samit Hirawat, EVP, CMO, Global Drug Development, Bristol Myers Squibb

Rich Moscicki, CMO & EVP, Science & Regulatory Advocacy, PhRMA

Sesha Neervannan, COO, Tarsus

Andrew Pecora, President & Chief Clinical Investigator, Celularity

Moderator: David Weinreich, EVP, Head, Global Clinical Development, Regeneron

4:40 pm

LONGWOOD FUND UPDATE 

Aleks Radovic-Moreno, Partner, Longwood Fund

3:20 pm

FIRESIDE CHAT

David Loew, CEO, Ipsen

Clay Siegall, CEO, Seagen

Moderator: Colin Hill, CEO, GNS Healthcare

1:30 pm

FIRESIDE CHAT

Kabir Nath, CEO, Otsuka US

Ray Sanchez, CMO, Cerevel Therapeutics

Moderator: John Adkisson, President & CEO, Fish & Richardson

7:00 am 

LONGWOOD FUND INTRODUCTION

Christoph Westphal, General Partner, Longwood Fund 

7:30 am

NEWCO TO ESTABLISHED: BUILDING A BIOTECH     

Al Gianchetti, CEO, XyloCor

Stuart Peltz, CEO, PTC Therapeutics

Saurabh Saha, CEO, Centessa Pharmaceuticals

Jan Skvarka, Executive Chair, DEM Bio

Lara Sullivan, CEO, Pyxis Oncology

Moderator: John Westwood, Partner, Oliver Wyman

8:00 am

BIG BIOPHARMA R&D 

Palani Kumaresan, Global Head, R&D, Roche Diagnostics

Phil Larsen, Global Head, Research & Early Development, Bayer

Jim List, Global Therapeutic Area Head, Cardiovascular, Metabolism, & Retina, Janssen 

Andy Plump, President, R&D, Takeda

Moderator: Luigi Gentile, CRO, BenchSci

10:20 am

FIRESIDE CHAT

Kiran Mazumdar-Shaw, Executive Chair, Biocon

John Sculley, former CEO, Pepsi/Apple

Moderator: David Steinberg, General Partner, Longwood Fund

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

THURSDAY, MAY 5, 2022

8:00 am

LONGWOOD FUND INTRODUCTION

David Steinberg, General Partner, Longwood Fund

8:30 am 

FIRESIDE CHAT

David Liu, Core Institute Member & Vice-Chair of the Faculty, Broad Institute

Phil Sharp, Nobel Laureate & Co-Founder, Alnylam/Biogen

Moderator: Christoph Westphal, General Partner, Longwood Fund 

8:50 am 

HARNESSING BIOMEDICAL INNOVATION

David Donabedian, Founding Executive, Interim CEO, DEM Bio 

Judy Chou, CEO, AltruBio 

Victor Dzau, President, National Academy of Medicine

Kai Wucherpfennig, Chair, Cancer Immunology and Virology, Dana-Farber Cancer Institute

Rogério Vivaldi, CEO, Sigilon Therapeutics

Moderator: Jeff Moore, President, MP Healthcare Venture Management

9:20 am

FROM DATA TO MEDICINE

Amira Barkal, CEO, Pheast

Fabrice Chouraqui, CEO, Cellarity

Anne Heatherington, Chief Data & Technology Officer, R&D, Takeda

Pratap Khedkar, CEO, ZS Associates

Sean McClain, Founder & CEO, Absci

Moderator: Jim Scibetta, CEO, ImmuneID

9:50 am

THE SHAKEUP IN TALENT RECRUITING AND RETENTION

Elizabeth Jeffords, CEO, Iolyx Therapeutics

Rahul Kakkar, Entrepreneur-Partner, Polaris

Rob Kowalski, Chief People & Organization Officer, Novartis

David Pyott, former CEO, Allergan, Inc.

Moderator: Julie Kampf, CEO, JBK Associates International

10:20 am

FIRESIDE CHAT

Stefan Oelrich, CEO, Bayer Pharmaceuticals

Paul Perreault, CEO, CSL

Moderator: Aaron Mitchell, Principal, ZS Associates

10:40 am

SCIENTIFIC INNOVATION: TRANSFERRING TECHNOLOGY FROM ACADEMIA

Anne Klibanski, President & CEO, Mass General Brigham

Josh Lehrer, CEO, Graphite Bio

Paul Schimmel, Professor, Cell & Molecular Biology, Scripps

Armon Sharei, CEO, SQZ Biotech

Moderator: Joel Marcus, JD, CPA, Executive Chairman & Founder, Alexandria Real Estate
Equities, Inc./Alexandria Venture Investments

11:10 am

CROSS-BORDER COLLABORATION

Stewart Geary, CMO, Eisai

Francesco Hofmann, Head, R&D, Pierre Fabre

Cristin Hubbard, Head, Global Partnering, Diagnostics, Roche

Ryan Richardson, Chief Strategy Offier, BioNTech

Carlo Russo, CMO, Genenta

Moderator: Stuart Mackey, Global Head, BD, Daiichi Sankyo

11:40 am

INNOVATION IN NEUROSCIENCE

Michael Hayden, CEO, Prilenia

Spyros Papapetropoulos, CMO, Vigil Neuroscience

Kerry Ressler, CSO, McLean Hospital

Moderator: Chandra Ramanathan, EIR, Mass General Brigham

12:10 pm

FIRESIDE CHAT

Kenneth Hillan, Chief Therapeutics Officer, 23andMe

Moderator: Maria Whitman, Managing Principal, Global Pharmaceutical & Biotech Industry, ZS Associates

12:30 pm

INNOVATIVE PARTNERSHIPS

Phil Gotwals, Global Head, BD&L, Novartis Institutes for BioMedical Research

Jason Kelly, CEO, Ginkgo Bioworks

Bob Silverman, CBO, Rejuveron

Joanne Smith-Farrell, CEO, Be Biopharma

Moderator: Beth Shafer, Head, Neuroscience, Drug Discovery Sciences, & Externalization BD, Takeda

1:00 pm

ALIGNING PRIORITIES WITH THE BOARD

Piraye Beim, CEO, Celmatix

Kerrie Brady, CEO, OccuTera

Greg Fiore, CEO, Exacis

Shalabh Gupta, CEO, Unicycive Therapeutics

Shalini Sharp, Board member, Organon

Moderator: Roger Tung, CEO, Concert Pharmaceuticals

1:30 pm

THE NEXT WAVE OF TARGETED THERAPIES

Frank Laukien, Co-Chair, AACR Cancer Evolution Working Group

Brad Margus, CEO, Cerevance

Mark McKenna, CEO, Prometheus Biosciences

Loic Vincent, CSO, Affini-T Therapeutics

Krishnan Viswanadhan, President & COO, Be Bio

Moderator: Oliver Rosen, President & CMO, DynamiCure

2:00 pm

FIRESIDE CHAT

Dave Reese, EVP, R&D, Amgen

George Yancopoulos, President & CSO, Regeneron

Moderator: Christoph Westphal, General Partner, Longwood Fund 

2:20 pm

EXTERNAL INNOVATION

Jay Kim, CEO, K2B Therapeutics

Sophie Kornowski, Senior Partner, Gurnet Point Capital

Ronenn Roubenoff, Global Head, Translational Medicine Discovery and Profiling, Novartis Institutes for Biomedical Research

Heather Schwoebel, COO & CBO, Alloy Therapeutics

Moderator: Bruce Sunstein, Partner, Sunstein LLP

2:50 pm

SOURCING AND IDENTIFYING NOVEL TECHNOLOGY

Teresa Bitetti, President, Global Oncology, Takeda

Gabriele Brambilla, CEO, Alira Health

PJ Brooks, Deputy Director, Office of Rare Diseases Research, NCATS, NIH

Matthew Disney, Chair, Chemistry, Scripps

Moderator: Luba Greenwood, CEO, Kojin Therapeutics

3:20 pm 

FIRESIDE CHAT

Paul Hastings, CEO, Nkarta Therapeutics

Jeremy Levin, CEO, Ovid Therapeutics

Ted Love, CEO, Global Blood Therapeutics

Moderator: David Steinberg, General Partner, Longwood Fund

3:40 pm

NOVEL THERAPEUTIC MODALITIES

Jennifer Buell, CEO, MiNK Therapeutics

Doug Drysdale, CEO, Cybin

Iris Grossman, CSO, Eleven Therapeutics

Linda Marban, CEO, Capricor Therapeutics

Chris Thanos, CEO, Actym Therapeutics

Moderator: Zhen Su, CEO, Marengo Therapeutics

4:10 pm 

FINANCING INNOVATION

Fred Callori, Partner, Perceptive Advisors

Michael Ehlers, CSO & Venture Partner, Apple Tree Partners

Ansbert Gadicke, Managing Director, MPM Capital

Arjun Goyal, Managing Director, Vida Ventures

Bob More, Partner, Alta Partners

Moderator: Stephen Thau, Partner, Orrick

4:40 pm

LONGWOOD FUND UPDATE 

Aleks Radovic-Moreno, Partner, Longwood Fund

Fall Meeting 2022.PNG

Supporters

To learn more about getting involved contact sg@longwoodfund.com

alexandria-logo-1-300x200.png
Logo2020_Transparent_RGB.png
Catalystadvisors.jpg
XHPCweY.y6Rd7X99Xoq.1.jpg
Cybin-Logo-Blue.png
Cytiva
Untitled design (3).png
GNS_Healthcare_logo_edited.jpg
JBK.png
Jefferies_Logo_Black_300dpi (2).jpg
Klick logo.jpg
Medicilon Logo.jpg
logo.png
Orrick_Logo.jpg
SUN__Logo_Tag_Web_color.png
wipro-primary-logo-color-rbg.png
ZS_Logo_RGB_4x.png